MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC
* Patients must have CDK4 amplification or CDK6 amplification and tumor Rb protein expression by immunohistochemistry as determined by the MATCH screening assessment.
* Patients must not have breast cancer, mantle cell lymphoma, myeloma, or liposarcoma.
* Patients must not have known hypersensitivity to palbociclib or compounds of similar chemical or biologic composition.
* Patients must not have received prior therapy with a CDK4 or CDK6 inhibitor (including but not limited to palbociclib, abemaciclib, or ribociclib).
Multiple Tumor Types
Alison Conlin, M.D.
ECOG (Eastern Cooperative Oncology Group)
The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.